Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

ClinicalTrials.gov ID: NCT01461538

Public ClinicalTrials.gov record NCT01461538. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 15, 2026, 11:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an open-label, multicenter, phase 2 clinical trial to evaluate the antitumor activity of brentuximab vedotin as a single agent in patients with CD30-positive nonlymphomatous malignancies.

Study identification

NCT ID
NCT01461538
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Seagen Inc.
Industry
Enrollment
84 participants

Conditions and interventions

Eligibility (public fields only)

Age range
6 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2011
Primary completion
Nov 30, 2014
Completion
Nov 30, 2014
Last update posted
Mar 3, 2016

2011 – 2014

United States locations

U.S. sites
29
U.S. states
14
U.S. cities
27
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35294-3300
City of Hope Duarte California 91010-3000
PMK Medical Group Inc., DBA Ventura County Hematology Oncology Specialists Oxnard California 93030
Rocky Mountain Cancer Centers - Aurora Aurora Colorado 80012
Mayo Clinic Cancer Center Jacksonville Florida 32224
Ocala Oncology Center Ocala Florida 34471
Indiana University Simon Cancer Center Indianapolis Indiana 46202
Dana-Farber Cancer Institute Boston Massachusetts 02215
Minnesota Oncology Hematology P.A. Minneapolis Minnesota 55404
New York Oncology Hematology, P.C. Albany New York 12206
University Hospitals Case Medical Center Cleveland Ohio 44106-5055
Willamette Valley Cancer and Research / USOR Eugene Oregon 97401
Northwest Cancer Specialists, P.C. Tulatin Oregon 97062
St. Francis Hospital Greenville South Carolina 29605
Texas Oncology - Bedford Bedford Texas 76022
Texas Oncology - Medical City Dallas Dallas Texas 75230
Texas Oncology - Dallas Presbyterian Dallas Texas 75231
Texas Oncology Denton South Denton Texas 76210
Texas Oncology - Fort Worth 12th Avenue Fort Worth Texas 76104
MD Anderson Cancer Center / University of Texas Houston Texas 77030-4003
MD Anderson Cancer Center Leukemia Group Houston Texas 77030
Texas Oncology - Central Austin Cancer Center Round Rock Texas 78731
Cancer Centers of South Texas - HOAST San Antonio Texas 78229
Texas Oncology - Waco Waco Texas 76712
Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care Blacksburg Virginia 24060
Virginia Cancer Specialists, PC Fairfax Virginia 22031
Puget Sound Cancer Centers Edmonds Washington 98026
Cancer Care Northwest Spokane Valley Washington 99216
Yakima Valley Memorial Hospital / North Star Lodge Yakima Washington 98902

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01461538, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 3, 2016 · Synced Sep 15, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01461538 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →